Disease relevance of Prizidilol

• Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension [1].
• Oral prizidilol exerts its hypotensive effect by vasodilatation without reflex tachycardia [2].
• The effects of prizidilol, a novel antihypertensive agent with vasodilator and beta-adrenoceptor blocking actions, were compared with those of hydralazine and propranolol in conscious dogs with chronic atrioventricular block [3].

Psychiatry related information on Prizidilol

• It is concluded that prizidilol significantly reduces blood pressure both at rest and during mental stress and physical activity with only sight effects on heart rate, and with a very simple therapeutic scheme [4].

High impact information on Prizidilol

• Drugs with combined beta-blocking and vasodilating (or alpha-blocking) properties (prizidilol and labetalol) induced clear reduction in TRP [5].
• At higher concentrations (25-190 microM), prizidilol bound to the oxygen binding site of the enzyme and produced a type II difference spectrum [6].
• For a comparable effect on blood pressure effective renal plasma flow was significantly increased at rest by prizidilol (+9%) and decreased by propranolol (-13.6%); these patterns were maintained during exercise [7].
• 6 The results indicate that the acute effects of prizidilol on blood pressure and renal function are more marked in hypertensive than in normotensive subjects [8].
• Pulmonary effects in man of oral prizidilol hydrochloride (SK&F 92657), a new antihypertensive agent [2].

Chemical compound and disease context of Prizidilol

• Fourteen men with moderately severe essential hypertension were treated with prizidilol hydrochloride 400-700 mg once daily (mean +/- S.D. 612 +/- 56 mg/day) [9].
• Acute effects of prizidilol on blood pressure, heart rate, catecholamines, renin and aldosterone in essential hypertension [10].
• The cardiovascular effects of a new antihypertensive agent, prizidilol hydrochloride (SK&F 92657), have been evaluated in a group of 13 patients with mild to moderate essential hypertension, both at rest and during mental stress and isometric or dynamic exercise [4].

Biological context of Prizidilol

• Slight but significant decreases in heart rate were seen after moderate doses (mean: 447 mg once daily) of prizidilol [11].
• Acute effects of combined vasodilation and beta-adrenoceptor blockade with prizidilol on renal function [8].
• 4 The left ventricular ejection fraction, evaluated in five subjects, 45 min after the start of the infusion, was not altered by prizidilol hydrochloride, but the left ventricular area decreased significantly [12].
• We evaluated the clinical pharmacology of prizidilol, a compound with vasodilator and beta-blocking properties, in 12 hypertensive patients with normal renal function [13].
• Changes in blood pressure, fluid volumes and glomerular filtration rate during long-term treatment with prizidilol, an antihypertensive drug with combined vasodilatator and beta-adrenoceptor blocking actions [14].

Anatomical context of Prizidilol

• Prizidilol in essential hypertension: long-term effects on plasma volume, extracellular fluid volume, and central hemodynamics at rest and during exercise [15].
• The long term effects on blood pressure, body fluid volumes, glomerular filtration rate and plasma renin concentration were studied in 11 patients with essential hypertension during treatment with prizidilol, which is an antihypertensive compound with combined vasodilatator and beta-adrenoceptor blocking actions [14].
• Computer simulation studies indicate that the most prevalent metal complex of prizidilol in blood plasma is [Fe2+(Priz-)H+]2+ but that this only forms at very high drug concentrations [16].

Associations of Prizidilol with other chemical compounds

• Diastolic blood pressure was lowered to the same extent by both prizidilol and propranolol [2].
• Doses increasing flow by 50 ml/min (ED50) were 0.48, 0.24, 331, 0.3, and 51 micrograms for sulfinalol, MK 761, prizidilol, pindolol, and hydralazine, respectively, Intravenous injection of each agent reduced blood pressure of anesthetized, ganglion-blocked dogs [17].
• Nipradilol decreased plasma renin concentration in acute and subacute studies, whereas it was unchanged with prizidilol treatment [18].

Gene context of Prizidilol

• A sustained decrease in BP was observed for 10 h after prizidilol 800 mg (n = 9), with a maximum antihypertensive effect (mean reduction in supine BP 33/18 mmHg) 2.5 h after dosing, which coincided with the mean peak plasma concentration [19].
• Metal binding by pharmaceuticals. Part 4. A comparative investigation of the interaction of metal ions with hydralazine, prizidilol and related compounds [16].

Analytical, diagnostic and therapeutic context of Prizidilol

• 5. Cardiac performance, as evaluated by the PEP/LVET ratio, improved after treatment with prizidilol [20].
• The study was open and ambulatory, with an initial placebo period followed by dose titration of prizidilol [9].
• An assay for prizidilol in plasma and urine by high-performance liquid chromatography [21].
• The metal complexing properties of two antihypertensive drugs, hydralazine (1-hydrazinophthalazine) and prizidilol (a hydrazinopyridazine), and some related ligands, have been studied using potentiometry, elemental analysis, spectrophotometry and computer simulation [16].

References